{"id":"W2164455762","doi":"10.1016/j.eururo.2008.09.037","title":"Re: Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma","year":2008,"lang":"en","type":"letter","venue":"European Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Temsirolimus; Medicine; Renal cell carcinoma; Interferon alfa; Oncology; Internal medicine; Interferon; Alpha interferon; Discovery and development of mTOR inhibitors; Virology; PI3K/AKT/mTOR pathway; Apoptosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000265781,0.0009424539,0.001343733,0.0004122499,0.0001512229,0.00002290114,0.0005185113,0.0006534207,0.0004278779],"category_scores_gemma":[0.0001372504,0.000727053,0.0005655261,0.0001631938,0.0002688397,0.00005522648,0.0002371743,0.002039526,0.0007683404],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002976955,"about_ca_system_score_gemma":0.0002465879,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002219269,"about_ca_topic_score_gemma":0.00001198864,"domain_scores_codex":[0.9954053,0.0006694917,0.0009049314,0.001459232,0.0003960106,0.001165077],"domain_scores_gemma":[0.9970257,0.0004944184,0.0004959493,0.001592125,0.0001422493,0.0002495442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003587397,0.0001519387,0.0001971324,0.000388584,0.0001634036,0.03047165,0.0002239724,0.00000675337,0.001400111,0.000001157524,0.9616856,0.001722305],"study_design_scores_gemma":[0.006021385,0.01240489,0.001268242,0.00005405509,0.0006784112,0.001932797,0.00001554709,0.00001772726,0.00150467,0.000006989946,0.9755094,0.0005858764],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.1170514,0.009815884,0.0007631475,0.6372218,0.004441434,0.007410822,0.0005859063,0.0008526911,0.2218569],"genre_scores_gemma":[0.2095143,0.0003373333,0.001710165,0.6598819,0.00850244,0.0001982558,0.00337635,0.0007769558,0.1157023],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.1061547,"threshold_uncertainty_score":0.999518,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03724392434054155,"score_gpt":0.2547802718044395,"score_spread":0.217536347463898,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}